{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:04:07Z","timestamp":1791201847744,"version":"4.2.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T00:00:00Z","timestamp":1566259200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T00:00:00Z","timestamp":1566259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81800714"],"award-info":[{"award-number":["81800714"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12933-019-0914-1","type":"journal-article","created":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T13:00:48Z","timestamp":1566306048000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":144,"title":["Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction"],"prefix":"10.1186","volume":"18","author":[{"given":"Nannan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6262-866X","authenticated-orcid":false,"given":"Bin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuexing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangyun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2358-1023","authenticated-orcid":false,"given":"Guidong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yafeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,20]]},"reference":[{"issue":"4","key":"914_CR1","first-page":"369","volume":"10","author":"M Rigolli","year":"2013","unstructured":"Rigolli M, Whalley GA. Heart failure with preserved ejection fraction. J Geriatr Cardiol. 2013;10(4):369\u201376.","journal-title":"J Geriatr Cardiol"},{"issue":"3","key":"914_CR2","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.jacc.2003.07.046","volume":"43","author":"K Hogg","year":"2004","unstructured":"Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function: epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol. 2004;43(3):317\u201327.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"914_CR3","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1016\/S0735-1097(00)00908-6","volume":"36","author":"TJ Kolias","year":"2000","unstructured":"Kolias TJ, Aaronson KD, Armstrong WF. Doppler-derived dP\/dt and -dP\/dt predict survival in congestive heart failure. J Am Coll Cardiol. 2000;36(5):1594\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"914_CR4","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1056\/NEJMoa051530","volume":"355","author":"RS Bhatia","year":"2006","unstructured":"Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, Gong Y, Liu PP. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006;355(3):260\u20139.","journal-title":"N Engl J Med"},{"issue":"6","key":"914_CR5","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/eurheartj\/ehq426","volume":"32","author":"BA Borlaug","year":"2010","unstructured":"Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J. 2010;32(6):670\u20139.","journal-title":"Eur Heart J"},{"issue":"9","key":"914_CR6","doi-asserted-by":"publisher","first-page":"H1407","DOI":"10.1152\/ajpheart.00542.2015","volume":"309","author":"M Schwarzl","year":"2015","unstructured":"Schwarzl M, Hamdani N, Seiler S, Alogna A, Manninger M, Reilly S, Zirngast B, Kirsch A, Steendijk P, Verderber J. A porcine model of hypertensive cardiomyopathy: implications for heart failure with preserved ejection fraction. Am J Physiol Heart Circ Physiol. 2015;309(9):H1407\u201318.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"9","key":"914_CR7","doi-asserted-by":"publisher","first-page":"H1390","DOI":"10.1152\/ajpheart.00713.2015","volume":"309","author":"GE Kai Hu","year":"2015","unstructured":"Kai Hu GE. A new porcine model of hypertensive cardiomyopathy a helpful tool to explore the HFpEF mystique. Am J Physiol Heart Circ Physiol. 2015;309(9):H1390.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"4","key":"914_CR8","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","volume":"62","author":"WJ Paulus","year":"2013","unstructured":"Paulus WJ, Tsch\u00f6pe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62(4):263\u201371.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"914_CR9","first-page":"312","volume":"4","author":"C Franssen","year":"2016","unstructured":"Franssen C, Chen S, Unger A, Korkmaz HI, De Keulenaer GW, Tsch\u00f6pe C, Leite-Moreira AF, Musters R, Niessen HW, Linke WA. Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction. J Am Coll Cardiol Heart Fail. 2016;4(4):312\u201324.","journal-title":"J Am Coll Cardiol Heart Fail"},{"key":"914_CR10","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/4865756","author":"AB Gevaert","year":"2017","unstructured":"Gevaert AB, Lemmens K, Vrints CJ, Van Craenenbroeck EM. Targeting endothelial function to treat heart failure with preserved ejection fraction: the promise of exercise training. Oxid Med Cell Longevity. 2017. \n                    https:\/\/doi.org\/10.1155\/2017\/4865756\n                    \n                  .","journal-title":"Oxid Med Cell Longevity"},{"issue":"12","key":"914_CR11","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1080\/17425255.2018.1551877","volume":"14","author":"A Garcia-Ropero","year":"2018","unstructured":"Garcia-Ropero A, Badimon JJ, Santos-Gallego CG. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments. Expert Opin Drug Metab Toxicol. 2018;14(12):1287\u2013302.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"914_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12933-017-0511-0","volume":"16","author":"M Pfeifer","year":"2017","unstructured":"Pfeifer M, Townsend RR, Davies MJ, Vijapurkar U, Ren J. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis. Cardiovasc Diabetol. 2017;16(1):29.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"914_CR13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12933-017-0510-1","volume":"16","author":"C Ott","year":"2017","unstructured":"Ott C, Jumar A, Striepe K, Friedrich S, Karg MV, Bramlage P, Schmieder RE. A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation. Cardiovasc Diabetol. 2017;16(1):26.","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"914_CR14","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/dom.12670","volume":"18","author":"F Zaccardi","year":"2016","unstructured":"Zaccardi F, Webb D, Htike Z, Youssef D, Khunti K, Davies M. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab. 2016;18(8):783\u201394.","journal-title":"Diabetes Obes Metab"},{"issue":"22","key":"914_CR15","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"7","key":"914_CR16","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"4","key":"914_CR17","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"1","key":"914_CR18","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12933-018-0708-x","volume":"17","author":"DM Lee","year":"2018","unstructured":"Lee DM, Battson ML, Jarrell DK, Hou S, Ecton KE, Weir TL, Gentile CL. SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice. Cardiovasc Diabetol. 2018;17(1):62.","journal-title":"Cardiovasc Diabetol"},{"key":"914_CR19","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12933-014-0148-1","volume":"13","author":"B Lin","year":"2014","unstructured":"Lin B, Koibuchi N, Hasegawa Y, Sueta D, Toyama K, Uekawa K, Ma M, Nakagawa T, Kusaka H, Kim-Mitsuyama S. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol. 2014;13:148.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"914_CR20","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.2337\/db16-0733","volume":"66","author":"M Joubert","year":"2017","unstructured":"Joubert M, Jagu B, Montaigne D, Marechal X, Tesse A, Ayer A, Dollet L, Le May C, Toumaniantz G, Manrique A, et al. The sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents cardiomyopathy in a diabetic lipodystrophic mouse model. Diabetes. 2017;66(4):1030\u201340.","journal-title":"Diabetes"},{"issue":"3","key":"914_CR21","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10557-017-6734-1","volume":"31","author":"N Hammoudi","year":"2017","unstructured":"Hammoudi N, Jeong D, Singh R, Farhat A, Komajda M, Mayoux E, Hajjar R, Lebeche D. Empagliflozin improves left ventricular diastolic dysfunction in a genetic model of type 2 diabetes. Cardiovasc Drugs Ther. 2017;31(3):233\u201346.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"2","key":"914_CR22","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s10557-018-6786-x","volume":"32","author":"E Flores","year":"2018","unstructured":"Flores E, Santos-Gallego CG, Diaz-Mej\u00eda N, Badimon JJ. Do the SGLT-2 inhibitors offer more than hypoglycemic activity? Cardiovasc Drugs Ther. 2018;32(2):213\u201322.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"19","key":"914_CR23","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1056\/NEJMoa032566","volume":"350","author":"MR Zile","year":"2004","unstructured":"Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med. 2004;350(19):1953\u20139.","journal-title":"N Engl J Med"},{"issue":"16","key":"914_CR24","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1161\/CIRCULATIONAHA.107.716886","volume":"117","author":"D Westermann","year":"2008","unstructured":"Westermann D, Kasner M, Steendijk P, Spillmann F, Riad A, Weitmann K, Hoffmann W, Poller W, Pauschinger M, Schultheiss HP, et al. Role of left ventricular stiffness in heart failure with normal ejection fraction. Circulation. 2008;117(16):2051\u201360.","journal-title":"Circulation"},{"issue":"3","key":"914_CR25","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.hfc.2014.03.001","volume":"10","author":"MJ Andersen","year":"2014","unstructured":"Andersen MJ, Borlaug BA. Invasive hemodynamic characterization of heart failure with preserved ejection fraction. Heart Fail Clin. 2014;10(3):435\u201344.","journal-title":"Heart Fail Clin"},{"issue":"1","key":"914_CR26","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12933-018-0717-9","volume":"17","author":"D Matsutani","year":"2018","unstructured":"Matsutani D, Sakamoto M, Kayama Y, Takeda N, Horiuchi R, Utsunomiya K. Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes. Cardiovasc Diabetol. 2018;17(1):73.","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"914_CR27","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1111\/dom.12962","volume":"19","author":"R Chilton","year":"2017","unstructured":"Chilton R, Tikkanen I, Hehnke U, Woerle HJ, Johansen OE. Impact of empagliflozin on blood pressure in dipper and non-dipper patients with type 2 diabetes mellitus and hypertension. Diabetes Obes Metab. 2017;19(11):1620\u20134.","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"914_CR28","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/dom.12127","volume":"15","author":"HJ Lambers Heerspink","year":"2013","unstructured":"Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15(9):853\u201362.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"914_CR29","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1177\/1479164114559852","volume":"12","author":"SE Inzucchi","year":"2015","unstructured":"Inzucchi SE, Zinman B, Wanner C, Ferrari R, Fitchett D, Hantel S, Espadero R-M, Woerle H-J, Broedl UC, Johansen OE. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diabetes Vasc Dis Res. 2015;12(2):90\u2013100.","journal-title":"Diabetes Vasc Dis Res"},{"issue":"1","key":"914_CR30","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12933-017-0621-8","volume":"16","author":"A Solini","year":"2017","unstructured":"Solini A, Giannini L, Seghieri M, et al. Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study. Cardiovasc Diabetol. 2017;16(1):138.","journal-title":"Cardiovasc Diabetol"},{"issue":"10","key":"914_CR31","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1161\/CIRCULATIONAHA.112.000855","volume":"127","author":"K Kondo","year":"2013","unstructured":"Kondo K, Bhushan S, King AL, Prabhu SD, Hamid T, Koenig S, Murohara T, Predmore BL, Gojon G, Gojon G, et al. H2S protects against pressure overload-induced heart failure via upregulation of endothelial nitric oxide synthase. Circulation. 2013;127(10):1116\u201327.","journal-title":"Circulation"},{"issue":"2","key":"914_CR32","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/ptr.4708","volume":"27","author":"YH Kang","year":"2013","unstructured":"Kang YH, Kang JS, Shin HM. Vasodilatory effects of cinnamic acid via the nitric oxide\u2013cGMP\u2013PKG Pathway in rat thoracic aorta. Phytother Res. 2013;27(2):205\u201311.","journal-title":"Phytother Res"},{"issue":"1","key":"914_CR33","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12933-017-0529-3","volume":"16","author":"GP Fadini","year":"2017","unstructured":"Fadini GP, Bonora BM, Zatti G, et al. Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial. Cardiovasc Diabetol. 2017;16(1):42.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"914_CR34","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1445-5994.2009.02075.x","volume":"40","author":"M Luque","year":"2010","unstructured":"Luque M, De Rivas B, Divis\u00f3n J, M\u00e1rquez E, Sobreviela E, Investigators HSG. Relationship between renal function and heart failure in hypertensive patients. Intern Med J. 2010;40(1):76\u20139.","journal-title":"Intern Med J"},{"issue":"15","key":"914_CR35","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","volume":"73","author":"CG Santos-Gallego","year":"2019","unstructured":"Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, Ishikawa K, Watanabe S, Picatoste B, Flores E, Garcia-Ropero A, Sanz J, Hajjar RJ. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. J Am Coll Cardiol. 2019;73(15):1931\u201344.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"914_CR36","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s10557-018-06850-0","volume":"33","author":"CG Santos-Gallego","year":"2019","unstructured":"Santos-Gallego CG, Garcia-Ropero A, Mancini D, Pinney SP, Contreras JP, Fergus I, Abascal V, Moreno P, Atallah-Lajam F, Tamler R. Rationale and design of the EMPA-TROPISM Trial (ATRU-4): are the \u201ccardiac benefits\u201d of Empagliflozin independent of its hypoglycemic activity? Cardiovasc Drugs Ther. 2019;33(1):87\u201395.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1","key":"914_CR37","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12933-018-0775-z","volume":"17","author":"F Soga","year":"2018","unstructured":"Soga F, Tanaka H, Tatsumi K, Mochizuki Y, Sano H, Toki H, Matsumoto K, Shite J, Takaoka H, Doi T, et al. Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure. Cardiovasc Diabetol. 2018;17(1):132.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"914_CR38","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12933-016-0489-z","volume":"16","author":"J Habibi","year":"2017","unstructured":"Habibi J, Aroor AR, Sowers JR, Jia G, Hayden MR, Garro M, Barron B, Mayoux E, Rector RS, Whaley-Connell A, et al. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovasc Diabetol. 2017;16(1):9.","journal-title":"Cardiovasc Diabetol"},{"issue":"13","key":"914_CR39","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.jacc.2008.11.051","volume":"53","author":"CS Lam","year":"2009","unstructured":"Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol. 2009;53(13):1119\u201326.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"914_CR40","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/j.amjcard.2006.11.052","volume":"99","author":"J Kjaergaard","year":"2007","unstructured":"Kjaergaard J, Akkan D, Iversen KK, Kjoller E, K\u00f8ber L, Torp-Pedersen C, Hassager C. Prognostic importance of pulmonary hypertension in patients with heart failure. Am J Cardiol. 2007;99(8):1146\u201350.","journal-title":"Am J Cardiol"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-019-0914-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12933-019-0914-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-019-0914-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T23:54:27Z","timestamp":1597794867000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-019-0914-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,20]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["914"],"URL":"https:\/\/doi.org\/10.1186\/s12933-019-0914-1","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,20]]},"assertion":[{"value":"3 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Experimental protocols were approved by the Ethics Committee of Nanjing Medical University (Approval ID: 2019000030) and conformed to the Guide for the Care of Use of Laboratory Animals published by the US National Institute of Health (8th edition, revised, 2011).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"107"}}